OBJECTIVES: Compare patient-reported satisfaction and BOI with oral vs. injectable therapy for multiple myeloma (MM) among patients with relapsed/refractory (RR) disease. METHODS: Patients within the patient-powered research network, PatientsLikeMe (PLM; www.patientslikeme.com) were surveyed about their treatment experience and BOI. Eligible patients were ≥ 18 years, resided in the USA, and were currently on a treatment regimen comprised of either an all-oral therapy (oral users) or injectable therapy with or without oral medication (injectable users). Those with concomitant amyloidosis or other cancers in the past 5 years were excluded. Patients were classified as RR if they ever changed treatment due to disease progression or recurrence. Patients completed a web based self-administered survey using the Treatment Satisfaction Questionnaire for Medication (TSQM) and BOI questions related to MM. Outcomes of interest were compared in univariate analyses between oral and injectable users. RESULTS: In this interim analysis, among 32 respondents, mean age was 60 years (SD: 9), 86% were Caucasian, 15% were Hispanic, and 57% and 25% had an ECOG PS 0-1 and 2, respectively. Current use of an all-oral regimen was 44% (n=14/32), whereas 56% (n=18/32) were on an injectable regimen. Oral users tended to report better mean effectiveness (70 vs. 65, p = 0.465) and global satisfaction (56 vs. 51, p = 0.386), and significantly greater convenience (83 vs. 64, p < 0.01) with therapy than injectable users. Oral users had fewer provider treatment visits in the past 30-days (median: 1 vs. 3) and less time spent per visit (median: 68 vs. 120 minutes) compared with injectable users. CONCLUSIONS: Emerging data suggests that an all-oral regimen is associated with a higher level of convenience and a trend towards greater treatment satisfaction and lower healthcare resource use than an injectable regimen in RRMM. Patient productivity will be reported in the final analysis.